Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ:SNDX
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-1.24Last Year’s EPS
-0.85Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 03, 2025
|% Change Since: -13.30%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Positive
Syndax has achieved significant milestones with the approval and commercial launch of two first-in-class medicines, generating initial revenues and securing a strong financial position. However, challenges remain in achieving full market penetration and managing competition. The overall sentiment reflects a positive outlook with some areas needing attention.Company Guidance
During the Syndax Fourth Quarter and Full Year 2024 Earnings Conference Call, the company provided comprehensive guidance for the upcoming year. They reported a remarkable start with $7.7 million in net revenue from Revuforj's initial five-week launch, reflecting strong patient demand and efficient market access. The company aims to file a supplemental new drug application for Revuforj in relapsed or refractory mutant NPM1 AML by the second quarter, targeting a $2 billion market opportunity. Additionally, Syndax launched Niktimvo in partnership with Incyte for chronic GVHD, estimating a $1.5 to $2 billion addressable market. Financially, Syndax strengthened its position with a $350 million upfront payment from Royalty Pharma, maintaining $692.4 million in cash and investments. For 2025, the company projects R&D expenses of $260 to $280 million and combined R&D plus SG&A expenses of $415 to $435 million, with an expectation to reach profitability.FDA Approval of Two First-in-Class Medicines
In 2024, Syndax received FDA approval for Revuforj, a menin inhibitor for relapsed/refractory acute leukemia, and Niktimvo for chronic Graft versus Host Disease, marking the company's entry into product revenue with $7.7 million from Revuforj in the initial five weeks of launch.
Strong Financial Position and Partnerships
Syndax strengthened its balance sheet with $350 million from a deal with Royalty Pharma, positioning the company to fund operations through profitability. The company also launched Niktimvo in partnership with Incyte.
Positive Clinical Data for Revuforj
Clinical trials showed Revuforj's effectiveness in treating acute leukemias, with potential for label expansion to include mutant NPM1 AML, representing a $2 billion market opportunity.
Encouraging Commercial Launch of Revuforj
Revuforj generated $7.7 million in net revenue in a partial quarter, with strong early patient demand and positive feedback on product profile and accessibility.
Niktimvo Potential Market Opportunity
Niktimvo targets a $1.5 billion to $2 billion market for third-line or later chronic GVHD treatment in the US, with potential for further expansion into earlier lines of treatment and other diseases.
---
SNDX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SNDX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 03, 2025 | $15.64 | $15.48 | -1.02% |
| Nov 05, 2024 | $19.69 | $21.35 | +8.43% |
| Aug 01, 2024 | $22.00 | $21.04 | -4.36% |
| May 08, 2024 | $23.18 | $22.38 | -3.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Syndax Pharmaceuticals Inc (SNDX) report earnings?
Syndax Pharmaceuticals Inc (SNDX) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Syndax Pharmaceuticals Inc (SNDX) earnings time?
Syndax Pharmaceuticals Inc (SNDX) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SNDX EPS forecast?
SNDX EPS forecast for the fiscal quarter 2025 (Q1) is -1.24.
---